Skip to Content

Silver Sulfadiazine Topical Dosage

Applies to the following strengths: 1%

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Burns - External

Adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns: Apply to affected areas once or twice a day to a thickness of approximately 1/16 inch.

Whenever necessary, silver sulfadiazine topical should be reapplied to any areas from which it has been removed due to patient activity. The drug should be reapplied immediately after hydrotherapy.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available


Silver sulfadiazine topical is contraindicated in pregnant women approaching or at term, premature infants, or newborn infants during the first 2 months of life, because the drug is known to increase the possibility of kernicterus.

There is potential cross sensitivity between silver sulfadiazine topical and other sulfonamides. If allergic reactions associated with silver sulfadiazine topical occur, therapy continuation should be weighed against the potential risks of the particular allergic reaction.

In some patients with glucose-6-phosphate dehydrogenase deficiency, the use of silver sulfadiazine topical may be hazardous, as hemolysis may occur.

If renal and hepatic functions become impaired and elimination of drug decreases, accumulation may occur and discontinuation of silver sulfadiazine topical should be weighed against the therapeutic benefit being achieved.

Serum sulfa concentrations may approach adult therapeutic levels during the treatment of burn wounds involving extensive areas of the body. Therefore, sulfa concentrations should be monitored in these patients. Renal function should be closely monitored and the urine should be checked for sulfa crystals.

Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.

Of the total number of patients in clinical studies of silver sulfadiazine topical, seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available

Other Comments

Prompt institution of appropriate regimens for care of the burned patient is of major importance and includes the control of shock and pain.

Burn wounds should be cleansed and debrided before administration of the drug. Silver sulfadiazine topical should be applied under sterile conditions. The burn areas should be covered with silver sulfadiazine topical at all times. Dressings are not required; however, if individual patient requirements make dressings necessary, they may be used.

Treatment should be continued until satisfactory healing has occurred or until the burn site is ready for grafting. The drug should not be removed from the therapeutic regimen while the chance of infection remains unless a significant adverse reaction occurs.